In collaboration with the CHU of Angers and the Institut de Cancérologie de l’Ouest, the Nantes establishment has received the CLIP² label (Centre labelled INCa of Early Phase), which rewards their participation in the joint CLIP²-ILIAD project. This project is among the 16 selected laureates at the national level, highlighting the significant contribution of the Pays de la Loire region to medical advancements.
Voir cette publication sur Instagram
A few details about the CLIP² label
The CLIP² label highlights establishments specialized in conducting early-phase clinical trials. These trials represent the first steps in evaluating the effectiveness of a new molecule on a small number of patients, before moving on to larger trial phases. This allows patients to quickly benefit from potential new treatments for cancer.
Nantes Hematology Department in the spotlight!
At the CHU of Nantes, it's the adult and pediatric hematology department that has been particularly recognized. This marks the fourth consecutive time that the CHU has received this label, awarded for a period of five years. This distinction reinforces the establishment's role in cancer research while providing financial and logistical support to continue this essential work.
Strong visibility!
Receiving this label brings great visibility, allowing the department to shine even brighter in the field of research.
thanks to the projects led by the CHU of Nantes, the CHU of Angers, and the Institute of Oncology of the West, especially with the medical industry. This recognition makes it easier to develop new technological and scientific partnerships, which are essential for advancing research and innovating in treatments.Promising research for the future!
Within this project, six research programs are currently underway: they include evaluations on the use of ionizing radiation to treat adult cancers as well as specific approaches for childhood leukemia.
This award highlights the commitment of the establishments in the Pays de la Loire to provide patients with cutting-edge treatments and to accelerate the fight against cancer. The CHU of Nantes and its partners continue to innovate in order to improve the quality of care and the prospects for recovery for patients.
A big shout-out to all the teams (heart with fingers)!
